查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884038

乙型肝炎治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032）

Hepatitis B Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 請詢問到貨日

價格

B型肝炎治療市場成長因素

由於乙型肝炎病毒 (HBV) 感染率的上升以及抗病毒治療的廣泛應用，全球乙型肝炎治療市場正經歷顯著增長。 2024 年，該市場規模為 23.3 億美元，預計到 2025 年將達到 24.8 億美元。預計到 2032 年，該市場將進一步顯著成長至 62.5 億美元，呈現強勁的上升趨勢。北美在 2024 年佔市場主導地位，佔全球市場佔有率的 53.65%，這主要得益於其先進的醫療保健基礎設施、較高的治療普及率以及在乙型肝炎治療領域強大的研發投入。

市場推動因素

市場成長的主要推動因素是乙型肝炎在全球範圍內的日益流行。乙型肝炎是由乙型肝炎病毒 (HBV) 引起的一種嚴重肝臟感染。其傳染途徑包括血液、體液、性接觸、母嬰傳染。根據世界衛生組織 (WHO，2024 年 4 月) 的數據，截至 2022 年，全球約有 2.54 億人（約佔世界人口的 3.3%）感染乙型肝炎，而慢性乙型肝炎患者中僅有 2.6% 接受治療。如此龐大的患者群體凸顯了有效治療的必要性，從而推動了已開發市場和新興市場的需求。

政府主導的各項舉措，例如中國於2025年1月啟動的 "支持中國到2030年消除病毒性肝炎對公眾健康的威脅" 計劃，正在進一步提高公眾意識、改善診斷率並促進治療。同樣，吉利德科學公司和葛蘭素史克公司等大型製藥公司的策略活動，也透過先進的研發和新療法的開發，支持市場擴張。

市場限制因子

慢性B型肝炎患者抗藥性的出現是一項重大挑戰。長期抗病毒治療，尤其是使用核苷/核苷酸類似物時，會導致病毒突變。研究表明，約30%的患者在一年內會產生拉米夫定抗藥性的乙肝病毒株，五年後，20-29%的患者會出現阿德福韋酯抗藥性。這可能導致治療效果降低、病毒量增加，並進展為嚴重的肝病，從而限制市場成長。

市場機會

在研產品和聯合療法提供了巨大的機會。各公司正在開發針對病毒 cccDNA 的新型療法，並將聯合療法整合以克服抗藥性並實現更好的病毒抑制。例如，智蒙生物製藥於 2022 年 8 月啟動了 ZM-H1505R 與恩替卡韋聯合用藥的 IIa 期臨床試驗，這表明人們對創新療法的興趣日益濃厚。

市場挑戰

B型肝炎的診斷、長期治療和管理成本高昂仍然是一個重大障礙，尤其是在中低收入國家。每日口服藥物和長期堅持治療的需求也帶來了挑戰，影響患者的依從性並導致抗藥性的產生。

市場趨勢

值得關注的趨勢包括針對乙型肝炎病毒 (HBV) cccDNA 的新一代療法的出現，展現了治癒性治療的潛力。例如，Precision Biosciences 公司公佈了 ELIMINATE-B 試驗的中期結果，該試驗評估了 PBGENE-HBV 基因編輯療法，旨在根除 HBeAg 陰性慢性乙型肝炎患者的 cccDNA，這表明治療正朝著治癒性方向發展。

細分市場分析

依藥物類別劃分，核苷類似物因其廣泛的處方歷史和高效性，在 2024 年佔市場主導地位。在沙烏地阿拉伯和阿聯酋，恩替卡韋錠的處方量佔所有病例的 73%。核苷類似物和乾擾素也貢獻顯著，預計新型療法將推動市場成長。

依年齡組劃分，成人市場佔主導地位，這主要歸因於較高的感染率，尤其是透過性接觸傳播的感染率。兒科治療正因疫苗接種計劃和適應症的增加而逐漸擴展。

依給藥途徑劃分，口服治療因其便利性和患者依從性，在2024年仍將佔市場主導地位。同時，注射劑型因其高生物利用度和療效而備受關注。

區域展望

北美市場預計將在2024年以12.5億美元的規模引領市場，主要得益於高盛行率、先進的治療手段以及公共衛生計畫。美國佔最大佔有率，這得益於其報銷政策和強大的研發實力。亞太地區是成長最快的地區，這主要得益於價格合理的仿製藥、不斷上升的盛行率以及政府的宣傳活動。歐洲市場正經歷穩定成長，而拉丁美洲和中東及非洲地區則作為新興市場，其成長動力主要來自於提高公眾意識和擴大治療可近性的努力。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家乙型肝炎流行率（2024 年）
  • 主要產業趨勢（新產品發表、併購、合作等）
  • 主要公司產品線分析
  • B型肝炎治療進展
  • 主要國家乙型肝炎疫苗接種率概述
  • 關稅的影響市場

第五章：全球B型肝炎治療市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依藥物類別劃分
    • 核苷類似物
    • 核苷酸類似物
    • 幹擾素
    • 其他
  • 市場分析、洞察與預測 - 依年齡組別劃分
    • 成人
    • 兒童
  • 市場分析、洞察與預測 - 依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測 - 依銷售管道劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美B型肝炎治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲B型肝炎治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區乙型肝炎治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲乙型肝炎治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東和非洲乙型肝炎治療市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 吉利德科學公司 (Gilead Sciences, Inc.)
    • 百時美施貴寶公司 (Bristol-Myers Squibb Company)
    • 葛蘭素史克公司 (GSK plc)
    • Excision BioTherapeutics, Inc.
    • Arbutus Biopharma
    • Assembly Biosciences, Inc.
    • Aligos Therapeutics
    • Barinthus生物療法
Product Code: FBI113651

Growth Factors of hepatitis B therapeutics Market

The global hepatitis B therapeutics market is witnessing substantial growth due to the rising prevalence of hepatitis B virus (HBV) infections and increased adoption of antiviral treatments. The market was valued at USD 2.33 billion in 2024, projected to reach USD 2.48 billion in 2025, and expected to grow significantly to USD 6.25 billion by 2032, reflecting a strong upward trend. North America dominated the market in 2024, accounting for 53.65% of the global share, owing to advanced healthcare infrastructure, high treatment adoption, and robust R&D investments in HBV therapies.

Market Drivers

The primary driver of market growth is the increasing global prevalence of hepatitis B, a severe liver infection caused by HBV. Transmission occurs via blood, body fluids, sexual contact, and from mother to child during birth. According to the World Health Organization (WHO, April 2024), approximately 254 million people worldwide-around 3.3% of the global population-were infected with hepatitis B in 2022, while only 2.6% of chronic HBV patients received treatment. This high patient population necessitates effective therapeutics, driving demand in both developed and emerging markets.

Government initiatives, such as China's "Supporting China's Action to Eliminate the Public Health Threat of Viral Hepatitis by 2030" program launched in January 2025, are further increasing awareness, improving diagnosis rates, and promoting therapeutic adoption. Similarly, strategic activities by key pharmaceutical players like Gilead Sciences, Inc. and GSK plc support market expansion through advanced R&D and novel treatment development.

Market Restraints

A significant challenge is the emergence of drug resistance in chronic hepatitis B patients. Long-term antiviral therapy can lead to mutations in the virus, particularly with nucleoside and nucleotide analogs. Studies indicate that around 30% of patients develop lamivudine-resistant HBV strains within a year, while resistance to adefovir dipivoxil appears in 20-29% of patients after five years. This reduces treatment efficacy, potentially leading to increased viral loads and progression to severe liver disease, thereby restraining market growth.

Market Opportunities

Emerging pipeline products and combination therapies offer significant opportunities. Companies are developing novel therapeutics targeting viral cccDNA and integrating combination treatments to overcome resistance and achieve better viral suppression. For example, Zhimeng Biopharma initiated a Phase IIa clinical trial in August 2022 for ZM-H1505R in combination with Entecavir, demonstrating the growing focus on innovative therapies.

Market Challenges

High treatment costs for diagnosis, long-term therapy, and management of hepatitis B remain a major barrier, particularly in low- and middle-income countries. Daily oral regimens and long-term adherence requirements also pose challenges, impacting patient compliance and contributing to the development of resistance.

Market Trends

A notable trend is the emergence of next-generation therapies targeting HBV cccDNA, offering potential curative options. For instance, Precision BioSciences, Inc. reported interim results from its ELIMINATE-B trial, evaluating PBGENE-HBV, a gene-editing therapy aimed at eradicating cccDNA in HBeAg-negative chronic HBV patients, signaling a shift toward curative treatments.

Segmentation Analysis

By drug class, nucleoside analogues dominated in 2024 due to widespread prescriptions and high efficacy, with entecavir tablets prescribed in 73% of cases in Saudi Arabia and UAE. Nucleotide analogues and interferons also contribute significantly, while novel therapies are expected to boost growth.

By age group, adults dominate the market due to higher transmission rates, especially through sexual contact. Pediatric therapeutics are expanding gradually due to vaccination programs and supplemental indications.

By route of administration, oral therapeutics led the market in 2024, favored for convenience and patient compliance, while parenteral forms are gaining traction due to better bioavailability and efficacy.

Regional Outlook

North America led in 2024 with USD 1.25 billion, driven by high prevalence, advanced treatment access, and public health programs. The U.S. accounts for the largest share, supported by reimbursement policies and strong R&D. Asia Pacific is the fastest-growing region, propelled by affordable generic drugs, increasing prevalence, and government campaigns. Europe is growing steadily, and Latin America and the Middle East & Africa are emerging markets with expanding awareness and access initiatives.

Competitive Landscape

Key players include Gilead Sciences, Inc., Bristol-Myers Squibb Company, GSK plc, Excision BioTherapeutics, Arbutus Biopharma, Assembly Biosciences, and Aligos Therapeutics. Companies are focusing on R&D, strategic collaborations, and novel drug development to expand market share.

Conclusion

With a market size of USD 2.33 billion in 2024, projected to grow to USD 2.48 billion in 2025 and USD 6.25 billion by 2032, the hepatitis B therapeutics market is poised for strong growth. Rising prevalence, emergence of next-generation therapies, government initiatives, and strategic efforts by pharmaceutical companies are driving the adoption of advanced treatments globally.

Segmentation By Drug Class

  • Nucleoside Analogues
  • Nucleotide Analogues
  • Interferons
  • Others

By Age Group

  • Adults
  • Pediatric

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Hepatitis B, By Key Countries, 2024
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Advancements in Hepatitis B Treatment
  • 4.5. Overview: Vaccination Coverage for Hepatitis B, Key Countries
  • 4.6. Impact of Tariffs on the Market

5. Global Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Nucleoside Analogues
    • 5.1.2. Nucleotide Analogues
    • 5.1.3. Interferons
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Adolts
    • 5.2.2. Pediatric
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Nucleoside Analogues
    • 6.1.2. Nucleotide Analogues
    • 6.1.3. Interferons
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Adolts
    • 6.2.2. Pediatric
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Nucleoside Analogues
    • 7.1.2. Nucleotide Analogues
    • 7.1.3. Interferons
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Adolts
    • 7.2.2. Pediatric
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Nucleoside Analogues
    • 8.1.2. Nucleotide Analogues
    • 8.1.3. Interferons
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Adolts
    • 8.2.2. Pediatric
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Nucleoside Analogues
    • 9.1.2. Nucleotide Analogues
    • 9.1.3. Interferons
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Adolts
    • 9.2.2. Pediatric
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis B Therapeutics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Nucleoside Analogues
    • 10.1.2. Nucleotide Analogues
    • 10.1.3. Interferons
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Adolts
    • 10.2.2. Pediatric
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Gilead Sciences, Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Bristol-Myers Squibb Company
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GSK plc
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Excision BioTherapeutics, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Arbutus Biopharma
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Assembly Biosciences, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Aligos Therapeutics
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Barinthus Biotherapeutics
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 2: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2019-2033
  • Table 3: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 4: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 7: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 8: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 12: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 13: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 14: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 17: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 18: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 22: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 23: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 24: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
  • Table 27: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 28: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 29: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Hepatitis B Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Figure 1: Global Hepatitis B Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2024 & 2032
  • Figure 3: Global Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 4: Global Hepatitis B Therapeutics Market Value Share (%), by Route of Administration 2024 & 2032
  • Figure 5: Global Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Hepatitis B Therapeutics Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 8: North America Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 9: North America Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 10: North America Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2024
  • Figure 11: North America Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 12: North America Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 13: North America Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Hepatitis B Therapeutics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Hepatitis B Therapeutics Market Value Share (%), By Country, 2024
  • Figure 17: Europe Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 18: Europe Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 19: Europe Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 20: Europe Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2024
  • Figure 21: Europe Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 22: Europe Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 23: Europe Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 28: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 29: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 30: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2024
  • Figure 31: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 33: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 38: Latin America Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 39: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 40: Latin America Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2024
  • Figure 41: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 42: Latin America Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 43: Latin America Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Drug Class, 2024 & 2032
  • Figure 48: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Drug Class, 2024
  • Figure 49: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 50: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Age Group, 2024
  • Figure 51: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Route of Administration, 2024
  • Figure 53: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Hepatitis B Therapeutics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Hepatitis B Therapeutics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Hepatitis B Therapeutics Market Share (%), By Company, 2024